Headlines

Opioid manufacturers and distributors Teva, Cardinal Health, AmerisourceBergen and McKesson avoided trial by reaching a $260 million settlement to resolve claims filed by two Ohio counties that alleged the companies played a role in causing the opioid crisis.

Congress is considering expanding current SEC whistleblower law to include protections for those who report potential securities violations internally to their employers.

Johnson & Johnson recalled a single lot of its baby powder on Friday, Oct. 18 after a sample tested positive asbestos.

Lawdragon 500 included 20 Motley Rice attorneys in its 2019 legal guide 500 Leading Plaintiff Financial Lawyers.

The City of North Charleston retroactively declared September 26 as Mesothelioma Awareness Day during a City Council meeting on Thursday, Oct. 10, 2019.

Charleston Mayor John Tecklenburg declared September 26 as Mesothelioma Awareness Day during a City Council meeting on Tuesday, Sept. 24, 2019. This marked the 8th year that Motley Rice has requested a proclamation and the day has been officially recognized in the City of Charleston.

The FDA warned e-cig manufacturer JUUL Labs Inc. regarding the company’s marketing of its unauthorized modified risk tobacco products, including marketing to youth that claimed e-cigarettes are “totally safe.”

As we pause to reflect, we stop not only to remember those who were lost and injured, but also to honor those who continue to seek justice and accountability for those responsible for the September 11, 2001 attacks.

The National Law Journal Elite Trial Lawyers recognized Motley Rice its work in navigating the Takata bankruptcy proceedings for personal injury victims as well as naming member attorney Fidelma Fitzpatrick as one of the 2019 Elite Women of the Plaintiffs’ Bar.

Generally speaking, manufacturers are required to submit individual reports to the FDA for each patient who sustains an injury or complication caused by a medical product. Established in 1997, Alternative Summary Reporting Program allowed manufacturers to bypass that standard by submitting quarterly summaries for cases that involve “well-known” complications. The FDA claims that this policy allowed the agency to “more efficiently review reports of well-known, well-understood adverse events.” However, the public was largely kept in the dark because this massive database was kept hidden, available only to the FDA – until now.